OClawVPS.com
Alpine Immune Sciences, Inc.
Edit

Alpine Immune Sciences, Inc.

https://www.alpineimmunesciences.com/
Last activity: 10.03.2026
Active
Categories: BioTechClinicDevelopmentPlatformProductResearchTechnology
Alpine Immune Sciences is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune and inflammatory diseases. We have two products in the clinic for inflammatory diseases and cancer, collaborations with world-class partners, and a robust development pipeline. Traded on NASDAQ under ticker ALPN.
Followers
520
Mentions
17
Location: United States, Washington, Seattle
Employees: 51-200
Total raised: $108M
Founded date: 2015

Investors 4

Funding Rounds 2

DateSeriesAmountInvestors
24.07.2020-$60MOmega Fund...
13.06.2016Series A$48MOrbiMed

Mentions in press and media 17

DateTitleDescription
10.03.2026Vertex passes key test in quest to treat kidney diseasesVertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company’s plan to expand into kidney disease. Vertex has faced questions about how it would div...
01.08.2025Frazier Life Sciences: $1.3 Billion Venture Fund ClosedFrazier Life Sciences (FLS), an investment firm focused on innovative therapeutics, announced the closing of Frazier Life Sciences XII, L.P. (FLS XII), with over $1.3 billion in capital commitments. The oversubscribed fund received strong s...
17.01.2025Innovent's Breakthrough in Pancreatic Cancer Treatment: A New Hope for PatientsIn the relentless battle against pancreatic cancer, a new warrior has emerged. Innovent Biologics, a biopharmaceutical company, has received Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration (NMPA)...
16.01.2025Ouro Medicines: $120 Million Raised For Developing Immune Reset TherapeuticsOuro Medicines, a biotechnology company creating immune reset therapeutics for people living with chronic immune-mediated diseases, announced its launch with $120 million in funding. And the company was launched by Monograph Capital in part...
04.10.2024Frazier Life Sciences: Over $630 Million Added To Evergreen Public FundFrazier Life Sciences (FLS), a healthcare investment firm focused on innovative therapeutics, announced it has closed on over $630 million in capital commitments to its evergreen Public Fund from new and existing investors in an oversubscri...
24.10.2022Alpine stops enrollment in cancer drug study after second patient death this yearA patient has died in a clinical trial testing an experimental Alpine Immune Sciences cancer immunotherapy, the second death in the study this year. The safety issue has prompted the company to stop enrollment in studies of the experimental...
20.09.2022Alpine Immune Sciences Announces Pricing of $100 Million Public Offering-
15.09.2021Three De­mo­c­rat reps op­pose Medicare drug pric­ing plan; Alpine Im­mune an­nounces pri­vate place­mentA trio of key De­moc­rats said yes­ter­day they will op­pose their par­ty’s plan to low­er drug prices — cre­at­ing a sub­stan­tial road­block for the De­moc­rats’ — and the White House’s — de­sired $3.5 tril­lion tax and spend­ing pack­age...
24.05.2019Life sci­ences fund rais­es €118M for its next round of bets; Gilead scraps Alpine al­liance→ A small but grow­ing transat­lantic biotech in­vestor is get­ting a fresh shot in the arm for its next round of bets. Foun­tain Health­care Part­ners has raised €118 mil­lion for Fund III, bring­ing its to­tal amount of cap­i­tal raised t...
01.02.2019Seattle Venture Capital Watch: Alpine Immune, Wyze, Aduro, Gaia & MoreShare Share on Facebook Share on Twitter LinkedIn Email Reprints Welcome to February! Whether your weekend plans involve watching the Super Bowl, tracking this year’s prediction by famed groundhog Punxsutawney Phil, or other activities, tak...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In